Login to Your Account

Spectrum ‘turnaround’ mode? Submits HDAC belinostat NDA

By Randy Osborne
Staff Writer

Tuesday, December 10, 2013
Shooting for an accelerated approval with priority review, Spectrum Pharmaceuticals Inc. submitted the new drug application (NDA) for belinostat, a pan-histone deacetylase (HDAC) inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL), and it expects a response from the FDA within 60 days.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription